National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, School of Pharmacy, The University of Mississippi, University, Mississippi 38677, United States.
Department of Bio-Molecular Sciences, The University of Mississippi, Mississippi 38677, United States.
Curr Med Chem. 2022;29(11):1827-1850. doi: 10.2174/0929867328666210623144658.
Novel therapeutic strategies are needed to address depression, a major neurological disorder affecting hundreds of millions of people worldwide. Cannabinoids and their synthetic derivatives have demonstrated numerous neurological activities and may have the potential to be developed into new treatments for depression. This review highlights cannabinoid (CB) receptors, monoamine oxidase (MAO), N-methyl-D-aspartate (NMDA) receptor, gammaaminobutyric acid (GABA) receptor, and cholecystokinin (CCK) receptor as key molecular targets of cannabinoids that are associated with depression. The anti-depressant activity of cannabinoids and their binding modes with cannabinoid receptors are discussed, providing insights into rational design and discovery of new cannabinoids or cannabimimetic agents with improved druggable properties.
需要新的治疗策略来治疗抑郁症，这是一种影响全球数亿人的主要神经疾病。大麻素及其合成衍生物表现出多种神经活性，有可能开发成治疗抑郁症的新方法。本综述重点介绍大麻素（CB）受体、单胺氧化酶（MAO）、N-甲基-D-天冬氨酸（NMDA）受体、γ-氨基丁酸（GABA）受体和胆囊收缩素（CCK）受体作为与抑郁症相关的大麻素的关键分子靶点。讨论了大麻素的抗抑郁活性及其与大麻素受体的结合模式，为新的大麻素或具有改善的可成药性的大麻类似物的合理设计和发现提供了见解。
